New drug combo before lung surgery shows promise in early trial
NCT ID NCT07450183
First seen Mar 07, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tests a drug called cemiplimab in people with stage II to IIIA lung cancer that can be removed with surgery. Participants will receive the drug before and after surgery to see if it helps destroy more cancer cells. The goal is to improve outcomes for patients whose tumors have a high level of a protein called PD-L1.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health
Detroit, Michigan, 48202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.